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Abstract 
BACKGROUND: Psoralen UVA (PUVA) and narrow-band UVB (NBUVB) chemophototherapy are treatment 
options for psoriasis. 
AIM: To compare the effectiveness of NBUVB with PUVA in Vietnamese psoriasis patients.  
METHODS: We conducted a non-randomized trial on 60 patients with plaque-type psoriasis (30 NBUVB, 30 
PUVA). Both regimens were thrice-weekly. The extent of lesion was assessed by the Psoriasis Area Severity 
Index (PASI). Clearance was defined as a ≥ 75% reduction in a follow-up PASI score from baseline. Patients with 
clearance were followed-up until 6 months after stopping treatment. Relapse was defined as 50% or more of the 
original extent. 
RESULTS: The proportion of patients achieving PASI75 was comparable (76.7% in NBUVB versus 80% in 
PUVA; p > 0.05). Patients in both groups had a similar number of sessions to achieve clearance but patients in 
the PUVA group exposed to a significantly higher cumulative UV dose. After six months, the relapse rate was 
higher in the NBUVB group compared with in the PUVA group (p > 0.05). 
CONCLUSION: Thrice weekly NBUVB is as effective as thrice weekly PUVA in treating psoriasis for Vietnamese 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Psoralen UVA (PUVA) chemophototherapy is 
a well-established and effective treatment for 
psoriasis. The main concern with PUVA is the risk of 
non-melanoma skin cancers as well as melanoma [1].  
Compared with PUVA, narrowband UVB 
(NBUVB) has some advantages: it does not require 
psoralen, is more accessible and less phototoxic or 
carcinogenic [2], [3]. Moreover, NBUVB did not have 
harmful effects on pregnant women [4] and Asian 
children [5].  
Despite these advantages, systemic PUVA is 
superior to NBUVB regarding the proportion of 
patients achieving clearance [6] and exhibited a 
longer duration of remission [7].  
Given the controversy in the indication of 
NBUVB and PUVA, we conducted a prospective trial 
to examine the effectiveness of NBUVB in treating 
psoriasis in comparison with PUVA in Vietnamese 
patients. 
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Methods 
 
Study design 
We conducted a non-randomized controlled 
trial on adults with chronic plaque-type psoriasis of 
moderate to a severe extent. Patients with 
Fitzpatrick's skin types III and IV were selected 
because they represented the local population. The 
decision to administer NBUVB or PUVA was based on 
the day of the week when patients were admitted 
(NBUVB on Monday, Wednesday, and Friday, and 
PUVA on Tuesday, Thursday, and Saturday); this 
allocation was done due to local logistic requirements. 
We excluded patients aged < 18 years and who had a 
history of skin cancer or solar keratoses, 
phototherapy, PUVA, or systemic therapy for psoriasis 
within the preceding three months. 
 
Study procedures 
Patients in the NBUVB group were treated 
three times weekly with a starting dose of 500 mJ/cm
2
. 
Next dose was increased by 20% of the previous, to a 
maximum of 2000 mJ/cm
2
. Patients underwent up to 
25 sessions. The dosage was adjusted if patients 
developed erythema. 
Patients in the PUVA group were treated 
three times weekly with a starting dose of 2 J/cm
2
, 
increasing by 20% each session, to a maximum of 15 
J/cm
2
 per dose. Patients underwent up to 25 sessions. 
The dosage was adjusted if patients developed 
erythema. Oral methoxsalen tablets (10 mg of 
Meladinine 10 mg tablet produced by CLS Pharma 
from French) at a dose of 0.6 mg/kg rounded up to the 
nearest 10 mg were taken 2 hours before treatment. 
Patients wore UV-A protective spectacles for 24 hours 
after treatment. 
We assessed the extent of lesions by the 
Psoriasis Area Severity Index (PASI). Clearance is 
defined as a 75% reduction in a follow-up PASI score 
from baseline (PASI75). PASI was measured by a 
clinician at recruitment (baseline) and repeated after 
every eight treatments (or earlier if study staff deemed 
patients had achieved PASI75). Patients who did not 
reach PASI75 would be managed according to local 
guidelines. 
We also monitored adverse effects of the 
therapy: erythema in both groups and symptoms after 
taking psoralen in patients treated with PUVA. The 
severity of erythema was divided into three grades: 
grade 1 (minimally perceptible erythema); grade 2 
(well-defined asymptomatic erythema) and grade 3 
(painful erythema persisting for more than 24 hours). 
We continued to follow up patients every 
month over six months after completing therapy. 
Relapse was defined as 50% or more of the original 
PASI index.  
Materials 
UV machine: Medisun 2800, whole body 
exposure units fitted with 22 fluorescent lamps (Philips 
TL100W/01), intensity (3.1 mW/cm
2
) was measured 
monthly. 
UVA machine: Houva II, whole body exposure 
units fitted with 24 UVA lamps, intensity (11.1 
mW/cm
2
) was measured monthly. 
Psoralene: Meladinine 10 mg tablet produced 
by CLS Pharma from French. 
 
Data collection and analysis 
Demographic and clinical data were recorded 
in a case report form. All data were entered into an 
electronic database and analysed with SPSS 20.0 
(IBM Corporation, USA). Descriptive data were 
described in proportion or mean (standard deviation). 
We used the Student’s t-test and the chi-square test 
to test for difference between continuous and 
categorical variables, respectively. The Kaplan-Meier 
curve and the Cox proportional hazard regression 
were used to compare the relapse rate between the 
two groups. 
 
Ethics 
The study was approved by the institutional 
review board of the National Hospital of Dermatology 
and Venereology, Vietnam. Informed consent was 
obtained from all patients. 
 
 
Results 
 
Between March 2014 and September 2015, 
we recruited 30 patients to the NBUVB group and 30 
to the PUVA group. The baseline characteristics of the 
two groups, with no significant difference, were 
presented in Table 1.  
Table 1: Baseline characteristics  
 NBUVB 
(n = 30) 
PUVA 
(n = 30) 
Male, n (%) 18 (60) 20 (66.7) 
Age, mean ± SD  35.8 ± 13.9 37.53 ± 15.19 
Duration, mean ± SD 7.8 ± 5.8 10.7 ± 8.4 
Itching, n (%) 24 (80) 23 (76.7) 
Skin type, n (%) 
 III 
 IV 
 
2 (6.7) 
28 (93.3) 
 
4 (13.3) 
26 (86.7) 
PASI score, mean ± SD 19.2 ± 7.7 19.5 ± 7.7 
SD: standard deviation. 
 
Forty-seven patients achieved clearance after 
the intervention, and the proportion was comparable 
between the two groups (73.3% in the NBUVB group 
versus 80% in the PUVA group, p > 0.05) as shown in 
Table 2.  
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Table 2: Treatment outcomes 
 NBUVB PUVA p 
Clearance, n (%) 22 (73.3) 24 (80%) > 0.05 
Number of sessions to clearance 19.7 ± 4.7 19.8 ± 4.8 > 0.05 
Cumulative dose to clearance(j/cm
2
) 26.2 ± 9.4 191.8 ± 79.7 < 0.01 
 
The number of sessions needed to achieve 
clearance was not different between the two groups; 
however, patients in the NBUVB exposed to a 
significantly lower cumulative UV dose. 
We followed up patients with clearance for six 
months. A slightly higher relapse rate in the NBUVB 
group, but Cox regression did not show any significant 
difference (p = 0.03) as presented in Figure 1. 
 
Figure 1: Kaplan-Meier’s curve of relapse after therapy 
 
Seven patients in the NBUVB group had 
grade 1 erythema after intervention while in the PUVA 
group, 3, 3, and 1 patient had grade 1, 2, and 3 
erythema, respectively. Nine patients had 
gastrointestinal complaints including nausea, emesis, 
and abdominal pain following meladinine 
administration (in the PUVA group). No patients had 
to discontinue treatment because of these side 
effects. 
 
 
Discussion 
 
This is a trial comparing the effectiveness and 
safety of narrowband UVB with psoralen UVA. Our 
main findings suggest NBUVB is comparable to PUVA 
regarding effectiveness but exposes patients to a 
lower UV. Dayal et al., (2010) also found similar 
results: both NBUVB and PUVA were effective, and 
PUVA had a lower number of sessions but a higher 
mean cumulative dose to achieve clearance [8]. 
Similar effectiveness between NBUVB and PUVA has 
also been shown in other studies [3], [9]. 
In our study, PASI75 was achieved after a 
mean number of sessions of 19.7, less than normally 
required (25 sessions). Dayal et al. used a lower 
starting dose (280 mJ/cm
2
) compared with our study 
(500 mJ/cm
2
) [8]. Also, we used the thrice-weekly 
regimen instead of a twice-weekly regimen. 
Kleinpenning et al., (2009) found that the high-dose 
regimen resulted in a shorter treatment course and a 
better outcome after 3-month follow-up but a similar 
cumulative dose [9]. 
In our study, the relapse rate was higher in 
the NBUVB group, but this difference was not 
statistically significant. The duration of remission in 
patients treated with PUVA has been reported to be 
longer than that in patients treated with NBUVB [10]. 
Despite superiority in effectiveness, NBUVB is 
considered the first-line option for some types of 
psoriasis [11] because it is more convenient and has 
fewer side effects. Although the two groups in our 
study had the same number of patients with erythema, 
patients treated with PUVA had higher severity (grade 
2 and 3 erythema were seen in four patients in the 
PUVA group but none in the NBUVB). One-third of the 
patients treated with PUVA also reported 
gastrointestinal symptoms after taking psoralen. While 
NBUVB is associated with a better safety profile, 
PUVA is, however, still recommended for patients who 
failed to respond or is refractory to NBUVB [11], [12], 
[13]. 
 In conclusion, thrice weekly NB UVB is as 
effective as thrice-weekly PUVA in treating psoriasis 
in Vietnamese patients. 
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